iZumi Bio Inc., a South San Francisco-based regenerative medicine company that uses induced pluripotent stem (iPS) cells, has raised $20 million in VC funding since its 2007 inception. Backers include Highland Capital Partners and Kleiner Perkins Caufield & Byers.
The funding amount was disclosed in a USA Today article, about how the company has forged a partnership with Kyoto University‘s Shinya Yamanaka. www.izumibio.com
Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!